

Clinical Commissioning Policy: Continuous aztreonam lysine for cystic fibrosis (all ages)

Reference: NHS England: 16001/P



NHS England INFORMATION READER BOX**Directorate**

Medical	Operations and Information	Specialised Commissioning
Nursing	Trans. & Corp. Ops.	Commissioning Strategy
Finance		

Publications Gateway Reference:**05527s**

Document Purpose	Policy
Document Name	Clinical Commissioning Policy 16001/P
Author	Specialised Commissioning Team
Publication Date	13 July 2016
Target Audience	CCG Clinical Leaders, Care Trust CEs, Foundation Trust CEs , Medical Directors, Directors of PH, Directors of Nursing, NHS England Regional Directors, NHS England Directors of Commissioning Operations, Directors of Finance, NHS Trust CEs

Additional Circulation List

Description	Not Routinely Commissioned - NHS England will not routinely commission this specialised treatment in accordance with the criteria described in this policy.
--------------------	---

Cross Reference	This document is part of a suite of policies with Gateway Reference 05527s.
------------------------	---

Superseded Docs (if applicable)	N/A
---	-----

Action Required	N/A
------------------------	-----

Timing / Deadlines (if applicable)	N/A
--	------------

Contact Details for further information	england.specialisedcommissioning@nhs.net
--	--

Document Status

This is a controlled document. Whilst this document may be printed, the electronic version posted on the intranet is the controlled copy. Any printed copies of this document are not controlled. As a controlled document, this document should not be saved onto local or network drives but should always be accessed from the intranet.

Clinical Commissioning Policy: Continuous aztreonam lysine for cystic fibrosis (all ages)

First published: July 2016

**Prepared by NHS England Specialised Services Clinical Reference Group for
Cystic Fibrosis**

Published by NHS England, in electronic format only.

Contents

1	Introduction	7
2	Definitions	8
3	Aims and Objectives	9
4	Epidemiology and Needs Assessment	9
5	Evidence Base	10
6	Documents which have informed this Policy	12
7	Date of Review	13
	References	14

Policy Statement

NHS England will not routinely commission continuous aztreonam lysine for cystic fibrosis (all ages) in accordance with the criteria outlined in this document. In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its use represents the best use of NHS resources. This policy document outlines the arrangements for funding of this treatment for the population in England.

Equality Statement

Promoting equality and addressing health inequalities are at the heart of NHS England's values. Throughout the development of the policies and processes cited in this document, we have:

- Given due regard to the need to eliminate discrimination, harassment and victimisation, to advance equality of opportunity, and to foster good relations between people who share a relevant protected characteristic (as cited under the Equality Act 2010) and those who do not share it; and
- Given regard to the need to reduce inequalities between patients in access to, and outcomes from healthcare services and to ensure services are provided in an integrated way where this might reduce health inequalities

Plain Language Summary

About cystic fibrosis

Cystic fibrosis (CF) is an inherited disease, caused by a faulty gene. This gene controls movement of salt and water in and out of cells. This means the lungs and digestive system become clogged with mucus – making it hard to breathe and digest food.

- CF is the most common, life-limiting, inherited disease in the United Kingdom (UK).
- Most cases are now diagnosed soon after birth.
- Around one in 25 of the population carry the faulty gene.

When people with CF have a build-up of mucus in the lungs it can make it difficult to clear the airway.

- This creates conditions in which bacteria can grow easily and well.
- Some of these bacteria can cause lung infections which keep coming back – these infections then damage the airways.
- This makes patient's less able to breathe freely – this seriously affects their quality of life.

About current treatments

Inhaled antibiotics are used to treat infection and reduce symptoms. Currently, three different antibiotics are used:

- tobramycin
- colistimethate sodium
- aztreonam lysine.

The antibiotics are usually used one after each other. This reduces the risk of the bacteria developing 'resistance'. Resistance is where a medicine no longer works because the bacteria adapt to the antibiotic. This means the bacteria keep causing the symptoms even if the patient is having treatment.

However, between about 1% and 5% of people living with CF cannot have tobramycin and colistimethate sodium. This is because:

- they cannot tolerate the medicines or
- they are allergic to both medicines.

This means that an option would be continuous treatment with aztreonam lysine.

What we have decided

NHS England has carefully reviewed the evidence to treat cystic fibrosis with continuous aztreonam lysine. We have concluded that there is not enough evidence to make the treatment available at this time.

1 Introduction

This document describes the evidence that has been considered by NHS England in formulating a proposal to not routinely commission continuous inhaled aztreonam lysine. Cystic fibrosis (CF) is the most common, life-limiting, recessively inherited disease in the UK, affecting over 10,000 people across the UK.

It is caused by a genetic mutation; specifically a mutation in a gene cystic fibrosis transmembrane conductance regulator (CFTR). The CFTR gene normally creates a protein that regulates levels of sodium and chloride in cells. If the gene is defective, it results in a build up of thick, sticky mucus in the body which is particularly damaging to the lungs, the gut and the pancreas, blocking the airways and the flow of digestive juices in the gut. This can result in problems with the digestion and absorption of food resulting in poor growth, and long-term infection and inflammation in the lungs (which is the main cause of morbidity and mortality).

Current standard treatments for cystic fibrosis aim to minimise the symptoms and include: (i) frequent chest physiotherapy (ii) specialist dietary advice, supplements and enzyme replacement therapy, and (iii) medication to relieve bronchospasm and inflammation in the lungs, reduce the viscosity of mucus in the airways or treat serious infection in the lungs.

Pseudomonas aeruginosa is the most frequent and important pathogen responsible for chronic infection in people with cystic fibrosis. NHS England currently has a formal commissioning policy for the use of inhaled therapies for patients (over the age of 6 years) with cystic fibrosis and chronic *pseudomonas aeruginosa* infection (A01/P/b 2014). This policy confirms that three antibiotics are funded in sequence: colistimethate sodium, tobramycin, and aztreonam lysine. Inhaled tobramycin and aztreonam lysine have been licensed for alternate month use due to theoretical concerns regarding bacterial resistance. As most people with cystic fibrosis will feel worse during the month with no antibiotic cover, alternating regimens are usually prescribed.

Aztreonam lysine is only considered if there is progressive loss of lung function (defined as greater than 2% per year decline in forced expiratory volume (FEV1) as % of predicted) or where there is continued need for intravenous therapy for

exacerbations i.e. more than two per year despite therapy with an alternating regimen of tobramycin and colistimethate sodium.

For a small number of patients, alternating treatment with aztreonam and tobramycin or colistimethate sodium may not be suitable due to intolerance or contraindications to both tobramycin and colistimethate sodium. For this subgroup, continuous aztreonam lysine may be the only available therapy that achieves adequate symptom relief for sustained periods.

2 Definitions

Cystic fibrosis (CF) is an inherited disease, meaning it is caused by a defect in an individual's genes.

The defective gene that causes CF is called the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The CFTR protein helps to produce mucus, which is a mixture of salts, water, sugars and proteins that cleanses, lubricates and protects many passage ways in the body including the lungs and pancreas. In CF, the defective CFTR protein does not allow chloride ions out of mucus-producing cells and the mucus becomes thick and sticky. In the pancreas, clogged passageways prevent secretion of digestive enzymes into the intestine causing serious impairment of digestion and mucus in the lungs may plug the airways preventing good air exchange. The mucus is also a rich source of nutrients for bacteria, leading to frequent infections.

CF is caused by a recessive allele (one of a number of forms of the same gene) inherited from both parents. If a patient has just one copy of the faulty allele, they are a carrier but will have no symptoms.

Pseudomonas aeruginosa is a type of bacteria that can cause long-term *Pseudomonas aeruginosa* infection in the lungs and is particularly prevalent in patients with CF due to the symptoms described above.

Inhaled aztreonam, a formulated lysine salt of the original monobactam antibiotic, is approved for the treatment of respiratory symptoms in patients over the age of 6 with cystic fibrosis who are colonised with *Pseudomonas aeruginosa*. Lyophilised

aztreonam lysine is diluted with 0.17% sodium chloride and administered using a nebuliser system.

Nebulised aztreonam lysine is licensed for use in patients over the age of 6 years.

3 Aims and Objectives

This policy proposition aims to define NHS England's commissioning position on continuous inhaled aztreonam lysine as part of the treatment pathway for adults and children with cystic fibrosis and chronic pseudomonas aeruginosa infections.

The objective is to ensure evidence based commissioning with the aim of improving outcomes for the use of continuous aztreonam lysine for the treatment of cystic fibrosis and chronic pseudomonas aeruginosa infections in adults and children.

4 Epidemiology and Needs Assessment

Cystic fibrosis (CF) is the most common, life-limiting, recessively inherited disease in the UK, affecting over 10,000 people. Cystic fibrosis is most common in white people of northern European descent. The condition is much less common in other ethnic groups.

There is currently no cure for cystic fibrosis, but many treatments are available to manage it, including physiotherapy, exercise, medication and nutrition. More than half of the cystic fibrosis patients in the UK will live past age 41 years.

Cystic fibrosis is generally progressive over time as lung tissue becomes more damaged. With age, patients are more likely to need longer courses of medication and longer, more frequent periods in hospital. Severely ill patients may need lung or heart transplants.

Approximately 70% of patients with cystic fibrosis (over the age of 6 years) are prescribed inhaled antibiotics. Consensus of clinical opinion estimates that 1-5% of those patients (c. 45 to 250 patients) may require treatment with continuous aztreonam lysine.

5 Evidence Base

NHS England has concluded that there is insufficient evidence to support the routine commissioning of the continuous use of aztreonam lysine as an option for patients with cystic fibrosis and chronic pseudomonas aeruginosa infections.

This evidence review was concerned with the cost and clinical effectiveness of continuous treatment with aztreonam lysine via a nebuliser, in adults and children with cystic fibrosis who have chronic infection with *Pseudomonas aeruginosa*.

In summary, no published evidence was found for the continuous use of inhaled aztreonam lysine (AZLI). Furthermore there is currently no published evidence comparing continuous aztreonam lysine and cyclical aztreonam lysine (28 days on AZLI followed by 28 days on a different antibiotic).

There is level 1 evidence for the clinical effectiveness of aztreonam lysine (AZLI) to treat infection by *Pseudomonas aeruginosa* (*P. aeruginosa*), compared to a placebo. There is also evidence from one randomised control trial (RCT) to support the superiority in clinical effectiveness of AZLI compared to tobramycin, coming from one RCT. A single study found that AZLI use was more cost effective than tobramycin.

All of the studies examined either a period of 28 days using AZLI or a cycle of using AZLI for 28 days, followed by 28 days with no antibiotics. There is evidence extrapolated from a single level 1 study that 28 days on tobramycin maintains the clinical benefits of 28 days on AZLI.

Clinical Evidence Review Questions

Research question 1: Is continuous treatment with aztreonam lysine via a nebuliser clinically effective in adults and children with cystic fibrosis who have chronic infection with *Pseudomonas aeruginosa*?

There is level 1 evidence for the efficacy of AZLI compared to a placebo. An often used measure of clinical effectiveness is to measure the percentage change, from the baseline value measured before the trial, in forced expiratory volume in 1 second (% change from baseline (%CFB) in FEV1). Three RCTs have all found, at the end of a 28 day trial, an improvement in the %CFB in FEV1 of between 0.3 to 8% in the AZLI arm and a deterioration in the placebo arm of between -2 to -2.5% (McCoy et al.

2008; Retsch-Bogart et al., 2009; Wainwright et al., 2011). Other metrics, such as the change in respiratory symptoms scale of the revised cystic fibrosis questionnaire (CFQ-R RSS) also demonstrate analogous improvements, compared with a placebo.

Likewise there is level 1 evidence that AZLI is superior to TOB, coming from the RCT (Assael et al., 2013), that compared the 75 mg AZLI, taken three times a day, in 28 days on / 28 days off cycles, with a similar TOB treatment. At the end of a 28 day cycle the mean %CFB in FEV1 was 8.4% for AZLI compared with 0.55% for TOB. During the off cycle there was an observed deterioration, but after three cycles there was still an overall improvement of 2.05%, compared with TOB at -0.66%. The study also found that, compared with TOB, patients treated with AZLI had:

- fewer hospitalisations (p=0.044)
- lower CFQ-R RSS scores (p=0.005)
- fewer respiratory events, needing additional antibiotics (p=0.004)

It also should be noted that the trial had an extension in which all patients received AZLI in a 28 days on / 28 days off cycle and there was no difference between the patients who had received TOB/AZLI and those receiving AZLI/AZLI. The deterioration in %CFB in FEV1 during the off periods was observed in all trials. There is also level 2 evidence that the improvement in FEV1 is greater when AZLI is being taken three times a day compared to when it is being taken twice a day (Oermann et al., 2010).

The only RCT identified that examined the continuous use of antibiotics for longer than 28 days was (Trapnell et al., 2012), which used 28 days of AZLI to establish a consistent baseline for a TOB trial. There is evidence extrapolated from a level 1 study that 28 days on TOB maintains the benefits of 28 days on AZLI, but no further improvement in FEV1 is made.

In terms of safety outcomes, patients with chronic pseudomonas aeruginosa infections display a wide range of adverse events. The most common of these is coughing (30-80%), but also pyrexia, oropharyngeal pain, dyspnoea and many others. In the majority of trials, there was no statistically significant difference between the rates of adverse events in the trial and placebo arm. One exception to

this was (Retsch-Bogart et al., 2009) found AZLI treated patients had a lower incidence of productive cough than placebo treated patients, but this was based on a small sample size (31 of 160 patients) and was not observed in other trials. Likewise there was no statistically significant difference in the numbers of adverse events in patients treated with AZLI, compared with those treated with TOB (Assael et al., 2013).

Research question 2: Is continuous treatment with aztreonam lysine via a nebuliser cost effective in adults and children with cystic fibrosis who have chronic infection with *Pseudomonas aeruginosa*?

One study was found that compared the cost of AZLI, taken three times a day on a 28 day on/28 day off cycle, with an analogous TOB treatment (Schechter et al., 2015). The study found that the total cost over 3 years of AZLI was 16% less than TOB (AZLI: £148,710 TOB: £176,268) [Original figures provided in US dollars and converted to the nearest full pound based on conversion rate on 17/11/2015 of £1 to \$1.52 and is provided as a guideline for comparison only]. This saving was predominantly coming from the assumed reduction in hospitalisation, with a slight reduction in drug costs. It was also based on a US healthcare model. The study also found AZLI marginally increased the number of quality adjusted life years.

A final point which is noteworthy is that, with the exception of (Trapnell et al., 2012), all of the RCTs were funded by Gilead, sole manufacturer of Cayston (trademark name for AZLI). Also there was considerable overlap in the authors of the majority of the RCTs and that many of these authors had received grants from Gilead, notably Gibson (2006), McCoy (2008), Oermann (2011), Retsch-Bogart (2009) and Wainwright (2011).

6 Documents which have informed this Policy

NHS England Clinical Commissioning Policy: Inhaled Therapy for Adults and Children with Cystic Fibrosis (A01/P/b 2014).

7 Date of Review

This document will be reviewed when information is received which indicates that the policy requires revision.

References

Assael, Baroukh M.; Pressler, Tacjana; Bilton, Diana; Fayon, Michael; Fischer, Rainald; Chiron, Raphael; LaRosa, Mario; Knoop, Christiane; McElvaney, Noel; Lewis, Sandra A.; Bresnik, Mark; Montgomery, A. Bruce; Oermann, Christopher M.; AZLI Active Comparator Study Group. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. *J. Cyst. Fibros.* 2013

Gibson, Ronald L.; Retsch-Bogart, George Z.; Oermann, Christopher; Milla, Carlos; Pilewski, Joseph; Daines, Cori; Ahrens, Richard; Leon, Kevin; Cohen, Morty; McNamara, Sharon; Callahan, Tracy L.; Markus, Richard; Burns, Jane L.. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. *Pediatr. Pulmonol.* 2006

McCoy, Karen S.; Quittner, Alexandra L.; Oermann, Christopher M.; Gibson, Ronald L.; Retsch-Bogart, George Z.; Montgomery, A. Bruce. Inhaled aztreonam lysine for chronic airway *Pseudomonas aeruginosa* in cystic fibrosis. *Am. J. Respir. Crit. Care Med.* 2008

Oermann, Christopher M.; McCoy, Karen S.; Retsch-Bogart, George Z.; Gibson, Ronald L.; McKevitt, Matthew; Montgomery, A. Bruce. *Pseudomonas aeruginosa* antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI). *J. Antimicrob. Chemother.* 2011

Retsch-Bogart, George Z.; Quittner, Alexandra L.; Gibson, Ronald L.; Oermann, Christopher M.; McCoy, Karen S.; Montgomery, A. Bruce; Cooper, Peter J.. Efficacy and safety of inhaled aztreonam lysine for airway *pseudomonas* in cystic fibrosis. *Chest.* 2009

Schechter, Michael S.; Trueman, David; Farquharson, Rachel; Higuchi, Keiko; Daines, Cori L.. Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis. An economic evaluation. *Ann Am Thorac Soc.* 2015

OFFICIAL

Trapnell, Bruce C.; McColley, Susanna A.; Kissner, Dana G.; Rolfe, Mark W.; Rosen, Jonathan M.; McKeivitt, Matthew; Moorehead, Lisa; Montgomery, A. Bruce; Geller, David E.; Phase 2 FTI Study Group. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. *Am. J. Respir. Crit. Care Med.* 2012

Wainwright, C. E.; Quittner, A. L.; Geller, D. E.; Nakamura, C.; Wooldridge, J. L.; Gibson, R. L.; Lewis, S.; Montgomery, A. B.. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and *P. aeruginosa*. *J. Cyst. Fibros.* 2011